This modification is to add additional quantity of 68 each of the MaxiPrep (1mg-2mg). This brings the total of 109 for the MaxiPrep (1mg-2mg). The closing date of July 26, 2010 5:00pm (EDST) is extended to a response date of July 30, 2010 5:00pm (EDST).
This is a combined Synopsis/Solicitation/Notice of Intent for commercial items prepared in accordance with the format in FAR Subpart 12.6, as supplemented with additional information included in this notice. This announcement constitutes the only solicitation; quotations are not being requested and a written solicitation will not be issued for the solicitation number NOI10132 a Notice of Intent. The incorporated provisions and clauses are those in effect through Federal Acquisition Circular FAC2005-42, dated June 16, 2010. This acquisition will be processed under Simplified Acquisition Procedures (SAP) and is not a Small Business Set-Aside. The associated North American Industry Classification System (NAICS) Code is 541380, which has a business size standard of 500 employees. The National Institute of Allergy and Infectious Diseases (NIAID) intends to procure from ACGT on a sole source MaxiPrep (1mg-2mg/quantity-41 each), and MegaPrep (5mg/ quantity-31each) amount of resin-pure plasmid DNA. The bacterial growth and plasmid purification process will consist of the following: 1) each glycerol stock will be streaked into a fresh plate with the appropriate antibiotic and grown overnight; 2) if plasmid DNA is delivered, it will be sequenced and then transformed into competent JM109 cells or equivalent cells; 3) a bacterial colony will be selected and grown overnight in 3ml media with antibiotic, and the culture will be expanded by growing it overnight in 500ml media with antibiotic; 4) the plasmid DNA will be purified from the expanded growth with a resin based method; and 5) a glycerol stock will be created from the large culture and stored at -80C. The proposed contractor will guarantee the following: 1) purification of plasmid DNA with resin based method. 2) quantification and purity evaluation of each plasmid DNA, 3) final product identity verification with single-pass DNA sequencing and additional troubleshooting, if needed, prior to shipping, 4) free shipping of purified DNA, and 5) storage of bacterial glycerol stocks on-site for 1 year. Period of performance shall be one (1) year from date of award. The following factors shall be used to evaluate offers: 1) price, 2) capability to meet required specifications, 3) storage, and 4) delivery. Place of delivery Bethesda, Maryland 20892. The government will award a fixed price purchase order to the responsible contractor. The FOB terms are "Destination" and Net 30. FAR provisions and clauses that apply to this acquisition: FAR 52.212-1, Instructions to Offerors, Commercial Items; FAR 52.212-2, Evaluation - Commercial Items; FAR 52.212-3, Offeror Representations and Certifications - Commercial Items; FAR 52.212-4, Contract Terms and Conditions - Commercial Items; FAR 52.212-5, Contract Terms and Conditions Required to Implement Statutes of Executive Orders - Commercial Items; FAR 52.232.33, Payment by Electronic Funds Transfer-Center Contractor Registration; and 45.103 Responsibility and Liability for Government Property. In order to be considered for an award, an Offeror must have completed the online electronic Representations and Certifications located at http://orca.bpn.gov/ in accordance with FAR 4.1201 (a). By submission of an offer, the Offeror acknowledges the requirement that a prospective awardee shall be registered in the CCR at www.ccr.gov prior to award during performance, and through final payment of any contract, basic agreement, basic ordering agreement, or blanket purchasing agreement resulting from this solicitation. [Note: Lack of registration in the Central Contractor Registration will make an Offeror ineligible for award.] All responsible sources may submit an offer that will be considered by the Agency. Offers must be submitted no later than 5:00 P.M. Eastern Daylight Savings Time on July 26, 2010. For delivery of responses through the Postal Service, the address is NIH/NIAID/AMOB, 10401 Fernwood Drive, Room 2NE38B, MSC 4811, Bethesda, Maryland 20892-4811. E-mail and Fax submissions are not authorized. Request for information concerning this requirement are to be submitted in writing, and can be faxed to 301-480-8720, or e-mail to firstname.lastname@example.org. It is the vendor's responsibility to confirm receipts of all quotations and/or questions by the closing date of this announcement by contacting Janice Battle at (301) 402-2282. Collect calls will not be accepted.
Place of Performance
National Institutes of Health, NIAID Bethesda, Maryland 20892 United States